Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
1.240
-0.090 (-6.77%)
At close: Nov 20, 2026, 4:00 PM EST
1.249
+0.009 (0.71%)
After-hours: Nov 20, 2026, 7:34 PM EST
Seres Therapeutics Employees
Seres Therapeutics had 66 employees as of December 31, 2025. The number of employees decreased by 37 or 35.92% compared to the previous year. That makes Seres Therapeutics the 33,725th largest employer in the world and 4,419th in the United States.
Employees
66
Change (1Y)
-37
Growth (1Y)
-35.92%
Revenue / Employee
$32,197
Profits / Employee
-$711,409
Market Cap
12.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 66 | -37 | -35.92% |
| Dec 31, 2024 | 103 | -130 | -55.79% |
| Dec 31, 2023 | 233 | -198 | -45.94% |
| Dec 31, 2022 | 431 | 98 | 29.43% |
| Dec 31, 2021 | 333 | 178 | 114.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 113 |
| Acumen Pharmaceuticals | 61 |
| BeyondSpring | 44 |
| Passage Bio | 24 |
| Bolt Biotherapeutics | 23 |
| BioCardia | 21 |
| Actuate Therapeutics | 12 |
| Tvardi Therapeutics | 12 |
MCRB News
- 18 days ago - Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) - GlobeNewsWire
- 18 days ago - Seres Therapeutics Earnings release: Q3 2026 - Filings
- 18 days ago - Seres Therapeutics Quarterly report: Q3 2026 - Filings
- 19 days ago - Seres Therapeutics’ SER-155 cuts bloodstream infection risk 77% in study - TheFly
- 19 days ago - Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients - GlobeNewsWire
- 5 weeks ago - Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 - GlobeNewsWire
- 2 months ago - Seres Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 2 months ago - Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire